Bcal Diagnostics (ASX:BDX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Bcal Diagnostics (ASX:BDX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Results of Meeting
AGM 2026 Presentation
BREASTESTplus Research Presented at Lipidomic Conference
Letter to Genetic Signatures Ltd Shareholders
Investor Presentation - Transforming Cancer Detection
Change in substantial holding
BREASTESTplus 2 clinically validated
BCAL validates BREASTESTplus 2 for all breast densities ahead of November launch
BCAL Introduces Avantect Multi-Cancer Early Detection Test
BCAL launches Avantect Multi-Cancer blood test in Australia
Letter to Shareholders re Annual General Meeting
Notice of Annual General Meeting/Proxy Form
Clarification of BCAL's Position in Relation to GSS
BCAL Seeks Board Change at Genetic Signatures
Investor Presentation September 2026
Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
Appendix 4G and Corporate Governance Statement
Appendix 4E and Annual Report to shareholders
BCAL Diagnostics reports FY2026 loss, advances cancer detection tests, secures funding and leadership changes
BCAL Takes Interest in Genetic Signatures to 18.46%
BCAL Increases Stake in Genetic Signatures to 18.46% to Expand Diagnostic Platform
Notification regarding unquoted securities - BDX
Notification regarding unquoted securities - BDX
Proposed issue of securities - BDX
BCAL Secures Funding for FY2027 Update
BCAL Diagnostics updates on $10 million Convertible Note Facility and funding status
Bioshares Conference Investor Presentation
Quarterly Activities/Appendix 4C Cash Flow Report
BCAL Diagnostics advances cancer detection tests, secures funding, and invests strategically
